Skip to main content
Terug
Watch Compare

Alzamend Neuro, Inc.

Datakwaliteit: 83%
ALZN
NASDAQ Manufacturing Chemicals
€ 0,90
▲ € 0,04 (4,84%)
Marktkapitalisatie: 3,43 M
Prijs
€ 0,90
Marktkapitalisatie
3,43 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -11,84 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-317,66%
Onder sectorgemiddelde (-54,44%)
ROIC-179,78%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current RatioN/A
Interest Coverage-424,23

Waardering

PE (TTM|NTM)
-0,33 | -0,33
Boven sectorgemiddelde (-1,49)
P/B Ratio1,57
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -0,3 -1,5
P/B 1,6 1,6
ROE % -317,7 -54,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

1 analist
Buy
Huidig
€ 0,90
+2680.9%
Koersdoel
€ 25,00
€ 25,00
€ 25,00
€ 25,00
Vooruitzicht
Forward K/W -0,33
Forward WPA -€ 2,60
Omzet Sch. 0,0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 2,60
-€ 2,60 – -€ 2,60
 0,0 1
FY2026 -€ 2,58
-€ 2,58 – -€ 2,58
 0,0 1

Winstverassingen

Laatste 6 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q12026 -€ 0,53 -€ 0,58 -9,4%
Q42025 -€ 1,96 -€ 0,30 +84,7%
Q32025 -€ 0,69 -€ 1,28 -85,5%
Q22025 -€ 2,70 -€ 9,48 -251,1%
2026-Q3 -€ 0,67 -€ 0,56 +16,4%
2026-Q2 -€ 0,67 -€ 0,05 +92,5%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -10,42 M
ROE -317,66% ROA -228,11%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -11,84 M
ROIC -179,78% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio N/A
Interest Coverage -424,23 Asset Turnover N/A
Working Capital N/A Tangible Book Value 2,18 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,33 Forward P/E -0,33
P/B Ratio 1,57 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -344,77%
Market Cap 3,43 M Enterprise Value 720.639,0
Per Share
EPS (Diluted TTM) -13,21 Revenue / Share N/A
FCF / Share -3,11 OCF / Share -3,11
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 113,64%
SBC-Adj. FCF -12,00 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -4,51 M -9,95 M -14,88 M -12,36 M -5,05 M
EPS (Diluted) -11,32 -14,70 -0,15 — —
Gross Profit — — — — —
Operating Income -4,50 M -9,94 M -14,87 M -12,32 M -4,95 M
EBITDA — — — — —
R&D Expenses 1,41 M 6,46 M 7,45 M 5,20 M 1,31 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 18.029,0 10.101,0 7.701,0 46.524,0 142.421,0
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 4,60 M 631.588,0 5,92 M 14,52 M 2,91 M
Total Liabilities 634.761,0 3,23 M 2,87 M 1,16 M —
Shareholders' Equity 3,97 M -2,59 M 3,05 M 13,35 M 2,01 M
Total Debt — — — — —
Cash & Equivalents 3,95 M 376.048,0 5,14 M 14,06 M 1,93 M
Current Assets 4,18 M 455.242,0 5,84 M 14,41 M 2,91 M
Current Liabilities — — 2,87 M 1,16 M 899.643,0